The trademark was filed by Novartis AG, a corporation established under the laws of the Swiss Confederation (the "Applicant"). The application was published for oppositions on September 12, 2022, and received one opposition filed on December 12, 2022 by HELIXOR Heilmittel GmbH on Likelihood of confusion. the opponent was represented by Rüger Abel Patentanwälte PartGmbB and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued December 12, 2022
The application was filed in English, and English was also language of all opposition proceedings (French was selected as the second language).